• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

热预处理对因子 VIII(FVIII)抑制剂检测中 FVIII 抗体水平的影响。

Effects of pre-analytical heat treatment in factor VIII (FVIII) inhibitor assays on FVIII antibody levels.

机构信息

Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, USA.

出版信息

Haemophilia. 2018 May;24(3):487-491. doi: 10.1111/hae.13435. Epub 2018 Feb 20.

DOI:10.1111/hae.13435
PMID:29461004
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6072565/
Abstract

INTRODUCTION

The use of pre-analytical heat treatment (PHT) with the Nijmegen-Bethesda assay (NBA) for inhibitors to factor VIII (FVIII) can remove/destroy infused or endogenous FVIII from patient plasma samples, allowing testing of recently infused patients with haemophilia. Two PHT methods have been described as follows: heating to 56°C for 30 minutes and heating to 58°C for 90 minutes. Data examining the effects of PHT on anti-FVIII IgG , the antibodies known to correlate most closely with the presence of FVIII inhibitors, are limited.

AIM

To assess the effect of PHT on the levels of detectable anti-FVIII IgG .

METHODS

Nijmegen-Bethesda assay-positive specimens were incubated at 56, 58 or 60°C for 90 minutes, and anti-FVIII IgG was measured by fluorescence immunoassay (FLI) at 30-minute intervals. The effects of PHT on the ability of recombinant FVIII (rFVIII) to inhibit detection of patient antibodies by FLI was also examined to assess the stability of rFVIII under the various PHT conditions tested.

RESULTS

Levels of anti-FVIII IgG showed little change following incubations at 56°C (mean 101% of original value at 30 minutes and 100% at 60 minutes) but decreased upon exposure to 58°C (mean 85% at 30 minutes and 66% at 60 minutes). In addition, heating to 56°C effectively decreased the ability of rFVIII to block antibody binding compared to unheated rFVIII.

CONCLUSION

The optimal temperature for PHT in the FVIII NBA is 56°C. Higher temperatures may lead to loss of inhibitory antibodies.

摘要

简介

使用 Nijmegen-Bethesda assay(NBA)对因子 VIII(FVIII)抑制剂进行预分析热处理(PHT),可以从患者血浆样本中去除/破坏输注或内源性 FVIII,从而可以对最近输注过的血友病患者进行检测。有两种 PHT 方法如下:加热至 56°C 30 分钟和加热至 58°C 90 分钟。关于 PHT 对抗 FVIII IgG 的影响的数据,目前研究有限,而抗 FVIII IgG 是与 FVIII 抑制剂存在最密切相关的抗体。

目的

评估 PHT 对可检测的抗 FVIII IgG 水平的影响。

方法

将 Nijmegen-Bethesda assay 阳性标本在 56°C、58°C 或 60°C 下孵育 90 分钟,并用荧光免疫测定法(FLI)在 30 分钟间隔测量抗 FVIII IgG。还检查了 PHT 对重组 FVIII(rFVIII)抑制 FLI 检测患者抗体能力的影响,以评估在测试的各种 PHT 条件下 rFVIII 的稳定性。

结果

在 56°C 孵育后,抗 FVIII IgG 水平变化不大(30 分钟时的原始值的平均为 101%,60 分钟时为 100%),但在暴露于 58°C 时下降(30 分钟时的平均为 85%,60 分钟时为 66%)。此外,与未加热的 rFVIII 相比,加热至 56°C 可有效降低 rFVIII 阻断抗体结合的能力。

结论

在 FVIII NBA 中,PHT 的最佳温度为 56°C。更高的温度可能导致抑制性抗体的丢失。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cae7/6072565/e6eb77cc18b7/nihms947608f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cae7/6072565/960de496ace2/nihms947608f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cae7/6072565/e6eb77cc18b7/nihms947608f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cae7/6072565/960de496ace2/nihms947608f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cae7/6072565/e6eb77cc18b7/nihms947608f2.jpg

相似文献

1
Effects of pre-analytical heat treatment in factor VIII (FVIII) inhibitor assays on FVIII antibody levels.热预处理对因子 VIII(FVIII)抑制剂检测中 FVIII 抗体水平的影响。
Haemophilia. 2018 May;24(3):487-491. doi: 10.1111/hae.13435. Epub 2018 Feb 20.
2
Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors.美国疾病控制与预防中心因子 VIII 抑制剂检测法的检测限和阳性阈值。
J Thromb Haemost. 2017 Oct;15(10):1971-1976. doi: 10.1111/jth.13795. Epub 2017 Sep 14.
3
Optimization of pre-analytical heat treatment for inhibitor detection in haemophilia A.甲型血友病中抑制剂检测的分析前热处理优化
Int J Lab Hematol. 2018 Oct;40(5):561-568. doi: 10.1111/ijlh.12862. Epub 2018 May 18.
4
Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay.运用基于荧光的免疫测定法对甲型血友病患者的抗凝血因子 VIII 免疫球蛋白谱进行表征分析。
J Thromb Haemost. 2015 Jan;13(1):47-53. doi: 10.1111/jth.12768. Epub 2014 Dec 11.
5
Diagnostic accuracy study of a factor VIII ELISA for detection of factor VIII antibodies in congenital and acquired haemophilia A.用于检测先天性和获得性甲型血友病中因子VIII抗体的因子VIII酶联免疫吸附测定的诊断准确性研究
Thromb Haemost. 2015 Oct;114(4):804-11. doi: 10.1160/TH14-12-1062. Epub 2015 Jun 11.
6
Clinical utility of sample preheat treatment in a modified Nijmegen-Bethesda assay (mNBA) for inhibitor monitoring in congenital and acquired haemophilia A: A single-centre four-year experience.改良奈梅亨-贝塞斯达检测法(mNBA)中样本预热处理在先天性和获得性血友病A抑制物监测中的临床应用:一项单中心四年经验
Haemophilia. 2020 Nov;26(6):e300-e307. doi: 10.1111/hae.14090. Epub 2020 Sep 6.
7
Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study.在美国血友病抑制剂研究中,基于凝血块、显色和荧光测定法比较因子 VIII 抑制剂的测量。
J Thromb Haemost. 2013 Jul;11(7):1300-9. doi: 10.1111/jth.12259.
8
Distinguishing lupus anticoagulants from factor VIII inhibitors in haemophilic and non-haemophilic patients.区分血友病和非血友病患者中的狼疮抗凝物和因子 VIII 抑制剂。
Haemophilia. 2018 Sep;24(5):807-814. doi: 10.1111/hae.13565. Epub 2018 Jul 13.
9
Evaluation of anti-factor VIII antibody levels in patients with haemophilia A receiving immune tolerance induction therapy or bypassing agents.评估接受免疫耐受诱导治疗或旁路药物治疗的血友病 A 患者的抗因子 VIII 抗体水平。
Haemophilia. 2021 Jan;27(1):e40-e50. doi: 10.1111/hae.14202. Epub 2020 Nov 20.
10
A longitudinal evaluation of anti-FVIII antibodies demonstrated IgG4 subclass is mainly correlated with high-titre inhibitor in haemophilia A patients.一项针对抗FVIII抗体的纵向评估表明,IgG4亚类主要与A型血友病患者的高滴度抑制物相关。
Haemophilia. 2015 Sep;21(5):686-92. doi: 10.1111/hae.12646. Epub 2015 Feb 24.

引用本文的文献

1
Turning up the heat: optimizing Bethesda assays for efanesoctocog alfa monitoring.提高检测灵敏度:优化用于监测依艾托考格α的贝塞斯达检测法。
Res Pract Thromb Haemost. 2025 Aug 5;9(6):102992. doi: 10.1016/j.rpth.2025.102992. eCollection 2025 Aug.
2
Pre-clinical evaluation of an enhanced-function factor VIII variant for durable hemophilia A gene therapy in male mice.增强功能因子 VIII 变异体在雄性小鼠中用于持久血友病 A 基因治疗的临床前评估。
Nat Commun. 2024 Aug 21;15(1):7193. doi: 10.1038/s41467-024-51296-8.
3
Diagnosis and laboratory monitoring of acquired hemophilia A.

本文引用的文献

1
Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors.美国疾病控制与预防中心因子 VIII 抑制剂检测法的检测限和阳性阈值。
J Thromb Haemost. 2017 Oct;15(10):1971-1976. doi: 10.1111/jth.13795. Epub 2017 Sep 14.
2
Detection and IgG subclass analysis of antibodies to factor VIII in multitransfused haemophiliacs and healthy individuals.
Haemophilia. 1996 Apr;2(2):88-94. doi: 10.1111/j.1365-2516.1996.tb00021.x.
3
Heat treatment of samples improve the performance of the Nijmegen-Bethesda assay in hemophilia A patients undergoing immune tolerance induction.对样本进行热处理可改善接受免疫耐受诱导的A型血友病患者的奈梅亨-贝塞斯达检测的性能。
获得性血友病 A 的诊断和实验室监测。
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):11-18. doi: 10.1182/hematology.2023000460.
4
Acquired Haemophilia A: A Review of What We Know.获得性血友病A:我们所了解的综述。
J Blood Med. 2022 Nov 23;13:691-710. doi: 10.2147/JBM.S342077. eCollection 2022.
5
A Diagnostic of Acquired Hemophilia Following PD1/PDL1 Inhibitors in Advanced Melanoma: The Experience of Two Patients and a Literature Review.晚期黑色素瘤患者使用PD1/PDL1抑制剂后获得性血友病的诊断:两例患者的经验及文献综述
Diagnostics (Basel). 2022 Oct 21;12(10):2559. doi: 10.3390/diagnostics12102559.
6
Acquired Hemophilia A: Current Guidance and Experience from Clinical Practice.获得性血友病A:当前临床实践指南与经验
J Blood Med. 2022 May 11;13:255-265. doi: 10.2147/JBM.S284804. eCollection 2022.
7
An Update on Laboratory Diagnostics in Haemophilia A and B.血友病 A 和 B 的实验室诊断进展。
Hamostaseologie. 2022 Aug;42(4):248-260. doi: 10.1055/a-1665-6232. Epub 2022 Feb 1.
8
Detailed analysis of anti-emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A.对血友病 A 患者血浆样本进行抗emicizumab 抗体降低药物疗效的详细分析。
J Thromb Haemost. 2021 Dec;19(12):2938-2946. doi: 10.1111/jth.15506. Epub 2021 Sep 28.
9
The effect of pathogen inactivation on cryoprecipitate: a functional and quantitative evaluation.病原体灭活对冷沉淀的影响:功能和定量评估
Blood Transfus. 2020 Nov;18(6):454-464. doi: 10.2450/2020.0077-20. Epub 2020 Aug 6.
10
Evaluation of CDC's Hemophilia Surveillance Program - Universal Data Collection (1998-2011) and Community Counts (2011-2019), United States.美国疾病预防控制中心血友病监测项目评估-通用数据收集(1998-2011)和社区计数(2011-2019)。
MMWR Surveill Summ. 2020 Sep 4;69(5):1-18. doi: 10.15585/mmwr.ss6905a1.
Thromb Res. 2015 Dec;136(6):1280-4. doi: 10.1016/j.thromres.2015.08.014. Epub 2015 Aug 28.
4
Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans.FVIII 特异性抗体的亲和力揭示了人类中和性和非中和性抗体之间的主要差异。
Blood. 2015 Feb 12;125(7):1180-8. doi: 10.1182/blood-2014-09-598268. Epub 2014 Dec 16.
5
Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay.运用基于荧光的免疫测定法对甲型血友病患者的抗凝血因子 VIII 免疫球蛋白谱进行表征分析。
J Thromb Haemost. 2015 Jan;13(1):47-53. doi: 10.1111/jth.12768. Epub 2014 Dec 11.
6
Definitions in hemophilia: communication from the SSC of the ISTH.血友病的定义:来自国际血栓与止血学会(ISTH)科学标准化委员会(SSC)的交流文件
J Thromb Haemost. 2014 Nov;12(11):1935-9. doi: 10.1111/jth.12672. Epub 2014 Sep 3.
7
Pre-analytical heat treatment and a FVIII ELISA improve Factor VIII antibody detection in acquired haemophilia A.分析前热处理和FVIII ELISA可提高获得性血友病A中VIII因子抗体的检测率。
Br J Haematol. 2014 Sep;166(6):953-6. doi: 10.1111/bjh.12923. Epub 2014 May 9.
8
A study of prospective surveillance for inhibitors among persons with haemophilia in the United States.美国血友病患者前瞻性抑制物监测研究。
Haemophilia. 2014 Mar;20(2):230-7. doi: 10.1111/hae.12302. Epub 2013 Nov 22.
9
Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients.健康个体和不同血友病 A 患者队列中针对因子 VIII 的抗体反应的特征不同。
Blood. 2013 Feb 7;121(6):1039-48. doi: 10.1182/blood-2012-07-444877. Epub 2012 Dec 12.
10
Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance.验证 Nijmegen-Bethesda 检测方法的改良,使其能够在替代治疗期间测量抑制剂,并便于抑制剂监测。
J Thromb Haemost. 2012 Jun;10(6):1055-61. doi: 10.1111/j.1538-7836.2012.04705.x.